CClinicalTrials.gg
Not yet recruitingNCT07733635VD-ASTHMAUpdated Jul 29, 2026

Vitamin D Status and Asthma Control, Pulmonary Function, and Oxidative Stress in Adults With Bronchial Asthma

An observational study in Bronchial Asthma, Vitamin D Deficiency and Pulmonary Function Impairment, sponsored by Sinai University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Sinai University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
134
Ages
18 Years and older
Sex
All
01

Study summary

Asthma is a chronic inflammatory airway disease associated with variable airflow limitation and persistent respiratory symptoms. Vitamin D has been proposed as a potential biomarker related to immune regulation, asthma control, pulmonary function, and oxidative stress balance.

This prospective cross-sectional observational study aims to investigate the association between serum 25-hydroxyvitamin D [25(OH)D] concentrations, asthma control, pulmonary function parameters, and erythrocyte oxidative stress biomarkers among Egyptian adults with bronchial asthma.

A total of 200 adult asthma patients will be recruited from Abbassia Chest Hospital, Cairo, Egypt. Participants will undergo clinical assessment, Asthma Control Test (ACT), post-bronchodilator spirometry, serum vitamin D measurement, and oxidative stress biomarker assessment including malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx), and reduced glutathione (GSH).

Participants will be categorized according to serum 25(OH)D concentrations into vitamin D deficient, insufficient, and sufficient groups.

No intervention or treatment assignment will be performed.

5. Detailed Description

Read the detailed description

This single-center cross-sectional observational study is designed to evaluate the association between serum vitamin D status and asthma-related clinical, functional, and biochemical characteristics among adult patients with bronchial asthma.

Eligible participants will be adults aged 18 years or older with confirmed bronchial asthma who are clinically stable at the time of assessment. Participants will be recruited from Abbassia Chest Hospital, Cairo, Egypt.

After obtaining written informed consent, demographic and clinical characteristics will be collected, including age, sex, body mass index (BMI), smoking status, asthma duration, previous exacerbations, hospitalization history, asthma severity, and current asthma medications including inhaled corticosteroids (ICS), long-acting β2 agonists (LABA), and short-acting β2 agonists (SABA).

Asthma control will be assessed using the Asthma Control Test (ACT), which evaluates symptom frequency, rescue medication use, activity limitation, and patient perception of asthma control.

Pulmonary function will be evaluated using post-bronchodilator spirometry according to ATS/ERS recommendations. The recorded parameters will include forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio.

Blood samples will be collected for serum 25(OH)D measurement using the DiaSorin LIAISON® 25 OH Vitamin D chemiluminescent immunoassay and assessment of oxidative stress biomarkers in erythrocyte hemolysates, including MDA, SOD, GPx, and GSH.

Participants will be classified according to vitamin D status:

Vitamin D deficient: \<20 ng/mL Vitamin D insufficient: 20-30 ng/mL Vitamin D sufficient: >30 ng/mL

The primary objective is to determine whether serum vitamin D concentration is associated with asthma control. Secondary objectives include evaluating associations with pulmonary function and oxidative stress biomarkers.

02

Conditions studied

  • Bronchial Asthma
  • Vitamin D Deficiency
  • Pulmonary Function Impairment
  • Oxidative Stress
  • Asthma
  • Antioxidant

Keywords

  • Vitamin D Deficiency
  • Bronchial Asthma
  • Pulmonary Function
  • Spirometry
  • Oxidative Stress
  • Malondialdehyde
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of 200 adult patients with confirmed bronchial asthma recruited from Abbassia Chest Hospital, Cairo, Egypt. Eligible participants will be adults aged ≥18 years with stable asthma at the time of assessment. Participants will be categorized according to serum 25-hydroxyvitamin D [25(OH)D] concentrations into vitamin D deficient (\<20 ng/mL), vitamin D insufficient (20-30 ng/mL), and vitamin D sufficient (>30 ng/mL) groups. Clinical characteristics, asthma control, pulmonary function, serum vitamin D status, and erythrocyte oxidative stress biomarkers will be assessed during a single study visit.

Inclusion criteria

  • Age ≥ 18 years.
  • Confirmed diagnosis of bronchial asthma.
  • Clinically stable at the time of assessment.
  • Availability of spirometry results.
  • Availability of laboratory investigations including serum 25(OH)D and oxidative stress biomarkers.

Exclusion criteria

Exclusion Criteria

  • Other chronic pulmonary diseases.
  • Active respiratory infection.
  • Malignancy.
  • Significant renal or hepatic disease.
  • Pregnancy.
  • Current vitamin D supplementation.
  • Other conditions known to markedly influence oxidative stress status.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
134 participants (estimated)
Patient registry
No

Groups and cohorts

  • Vitamin D Deficient Group

    Adults with bronchial asthma and serum 25-hydroxyvitamin D concentrations below 20 ng/mL.

  • Vitamin D Insufficient Group

    Adults with bronchial asthma and serum 25-hydroxyvitamin D concentrations between 20 and 30 ng/mL.

  • Vitamin D Sufficient Group

    Adults with bronchial asthma and serum 25-hydroxyvitamin D concentrations above 30 ng/mL.

05

What researchers measure

Primary outcomes

  1. Asthma Control Level Measured by Asthma Control Test (ACT) Score

    Assessment of asthma control using the Asthma Control Test (ACT) questionnaire, reported as an ACT score ranging from 0 to 25 points.

    Time frame: Single baseline assessment.

Secondary outcomes

  1. Pulmonary Function Parameters

    FEV1 % predicted FVC % predicted FEV1/FVC ratio

    Time frame: Single baseline assessment.

  2. Oxidative Stress Biomarkers

    Malondialdehyde (MDA) Superoxide dismutase (SOD) Glutathione peroxidase (GPx) Reduced glutathione (GSH)

    Time frame: Single baseline assessment.

  3. Serum Vitamin D Concentration

    Serum 25-hydroxyvitamin D concentration (ng/mL)

    Time frame: Single baseline assessment.

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared. The datasets contain potentially identifiable health information, and participant consent and institutional ethical approval did not include unrestricted public data sharing. Reasonable requests for access to de-identified data may be considered by the corresponding author, subject to institutional and ethical approval.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07733635
Lead sponsor
Sinai University
Responsible party
Amany Gomaa Atiaa (lecturer, Sinai University) — Principal investigator
First posted
Jul 29, 2026
Start date
Jul 26, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Feb 25, 2027 (estimated)
Last update
Jul 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion